Stemtech (STEK) Long-Term Deferred Tax (2016 - 2024)

Stemtech's (STEK) quarterly Long-Term Deferred Tax came in at $7.4 million in Q4 2024, up 47.5% quarter-over-quarter from $5.0 million in Q4 2021.

Stemtech (STEK) Long-Term Deferred Tax (2016 - 2024) Analysis & Trends

Stemtech has disclosed Long-Term Deferred Tax across 6 years of filings, most recently posting $7.4 million for Q4 2024.

Long-Term Deferred Tax for Q4 2024 came in at $7.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $7.4 million (changed N/A YoY), and the FY2024 annual result was $7.4 million, changed N/A from the prior year.
Long-Term Deferred Tax came in at $7.4 million for Q4 2024 at Stemtech, up from $5.0 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $7.4 million in Q4 2024 to a low of $5.0 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Stemtech	-	-	354,677.00

Download Data